Investment Rating - The report maintains a "Recommend" rating for the company, indicating a positive outlook for its future performance [2][9]. Core Views - The company plans to acquire a 51% stake in Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. and a 72.7272% stake in Inner Mongolia Shengxue Dacheng Pharmaceutical Co., Ltd. for a total price of 727 million yuan, which is expected to enhance its market position and operational synergy [2][4]. - Shengxue Dacheng is a leading player in the veterinary medicine sector, with a strong portfolio of products including key antibiotics, and has shown robust revenue and profit growth, significantly outpacing industry averages [8][9]. - The acquisition is anticipated to create complementary benefits between the two companies, leveraging their respective strengths in product lines, business types, and sales regions [8][9]. Financial Summary - The company’s total revenue is projected to grow from 6,017 million yuan in 2024 to 8,206 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 10.6% [9]. - Net profit is expected to rebound significantly from a loss in 2024 to a profit of 461 million yuan by 2027, reflecting a strong recovery trajectory [9]. - The earnings per share (EPS) is forecasted to increase from 0.07 yuan in 2024 to 0.45 yuan in 2027, indicating improved profitability [9]. Market Position and Performance - The company has maintained a stable financial performance with a debt-to-asset ratio of 28.26% and a consistent increase in revenue over the past nine years, demonstrating resilience against market fluctuations [5][9]. - The stock has shown a price target of 10.5 yuan, with the current price at 7.83 yuan, suggesting potential upside for investors [4][9].